DIGI-TECH PHARMA 2018
Wednesday, 05/02/2018 – 05/03/2018 08:30 am – 05:30 pm
Holiday Inn London – Kensington (TBC)
Wrights Lane, Kensington,
London, Kansas W8 5SP
Eventbrite
Cost: 530 euro

Emerging technologies are changing the landscape of Pharmaceutical industry and their relationship with their customers while creating new opportunities for collaboration. Pharma companies have to think beyond the pill and substantiate the value of their drugs in the real world, which would lead to a better patient outcome. Thus a necessity for partnership and collaboration with the healthcare provider is a must for pharmaceutical companies to be ahead of the game and make most use of the healthcare technologies, resources and tools that integrate with patient’s lifestyle which could definitely compliment the strengths of both pharma and healthcare.

The deployment of technology is now increasingly dominant in pharmaceutical R&D; the enhancements in data management and data integration are providing improvements to both the speed and quality of many clinical trial processes. The digital sensors connected to the Internet of Healthcare Things (IoHT) that is generating vast amount of Big Data is drawing the attention of pharmaceutical firms and moreover the Patient data is extremely valuable to drug companies as the analytics technology can be used to explore Big Data to reveal connections and patterns that allow the evolution of precision medication. Artificial intelligence has been a disruptive technological force in healthcare as a whole, but it is proving to have massive benefits in pharmaceuticals and drug discovery. The combination of AI, big data and IoT technologies will create new innovations and other eminent technologies like cloud computing, augmented reality, virtual reality, 3D printing and blockchain are being used extensively in the Pharmaceutical industry’s digital transformation.

Therefore this upcoming conference 2nd Annual Digi-Tech Pharma 2018, will provide a platform to all its participants an opportunity to interact, share and discuss the digitalization of Pharma industry. The conference will allow its participants to discuss the various challenges faced, new strategies, case studies and use of innovative ideas in the field of Digital Pharma IT. Also, to stay updated on the latest trends in digital, social media and mobile strategies required to overcome the obstructions in the transformation. This Digi-Tech Pharma 2018 is a unique platform in the Pharmaceutical Conferences which will allow IT leaders to share their technologies and strategies to help the pharma industries avail new opportunities to encourage partnerships and collaborations.

It gives us a great pleasure to welcoming you to this international 2nd Annual Digi-Tech Pharma 2018 conference.

Global Clinical Trials Connect 2018
Sunday, 04/25/2018 – 04/26/2018 08:30 am – 05:30 pm
Novotel London City South
53-61 Southwark Bridge Road London SE1 9HH United Kingdom,
London, Florida SE1 9HH
More Information
Cost: 530

The Global Clinical Trials Connect 2018 conference focuses on introducing pioneer technology, developing better patient engagement and collaborating strategies in clinical trials. With the right commitment and attention to detail, contract research organizations (CROs) and pharmaceutical companies can drive collaboration with greater efficiency.
The global pharmaceutical industry has seen a downturn in recent years because of the challenges and cost associated with pharmaceutical development, procrastination in drug development, etc. Clinical trials field is also faced with such challenges. Cases of failures, cost and delay are high. It is high time that we look into innovative strategies, new technologies, effective and quality collaborations to address these issues, which can cater to the needs of the patient and the industry. Due to complex clinical trials and bygone data standardization methods, we need algorithms and lucrative strategies that will enhance the clinical trials outcomes. There are vast data collected across clinical trial process, the standardization of these data will turn into an opportunity for companies to trap the information and raise clinical trial design, patient recruitment, monitoring insights and augment decision-making.
One response to this can be CROs and pharmaceutical companies can together work on diverse and varied clinical trial activities, also in near future we require joint effort for fulfilling outsourcing requirements and providing effective clinical trials.
This conference will bring together the industry experts and leaders across pharmaceutical, biotechnological and CRO’s for brainstorming on Case studies on innovation, collaboration and existing clinical data to headway the Clinical Trials process. Ethical considerations are given in this context and for this RBM are beginning to extend its concepts in Quality Risk Management; clinical trial predictive models are accumulated by enterprises, methodologies in trial design and many more.
It gives us a great pleasure to welcoming you to the Global Clinical Trials Connect 2018.
Key Highlights:
• Partnership & Collaboration – Sponsors, CROs, Sites and External Vendors
• Outsourcing strategies and models
• Patient centric clinical trials
• Real World Clinical Trial Strategies
• Electronic Clinical Outcome Assessment and Electronic Patient Reported Outcome
• Clinical Technology and Driving Innovation
• M-Health, Wearable and Consumer Technology
• Artificial Intelligence Technology in Clinical trials
• Patient Recruitment and Site selection
• Keeping the Patients Informed After the Trial – Post-Clinical Trial closed communities
• How to future proof your clinical operations
• Data Quality & Technology
• Big-Data and IoT in Clinical Trials
• Clinical Data Strategy & Analytics
• Implementing Risk Based Monitoring
• Streamlining R&D and lower costs in clinical trials
• Adaptive Trial Model
• Clinical Trial Auditing

Global Proteomics Conference
Sunday, 10/25/2017 – 09:00 am – 06:00 pm
JW Marriott Hotel Dubai Abu Baker Al Siddique Road, Hamarain Centre Deira | PO Box 16590 Dubai | UAE
JW Marriott Hotel Dubai Abu Baker Al Siddique Road, Hamarain Centre Deira | PO Box 16590 Dubai | UAE,
dubai, Florida 069120

Cost:

Meetings International proudly announces the Global Experts Meeting on Global Proteomics Conference scheduled during October 25-26, 2017 at. Dubai, UAE. Theme“Improved Understanding, Latest Advances And Future Prospects In The Field Of Proteomics”

Global Proteomics conference covers various aspects of
• Proteomics & System Biology
• Chemical Proteomics & Profiling Drug Targets
• Multiomics for Precision Medicine & Systems Biology
• Analytical Proteomics & Genomics
• Bioinformatics and Computational Proteomics
• Clinical & Translational Proteomics
• Innovative Fractionation & Enrichment Techniques
• Proteomics Technologies
• Biomedical Sciences In Proteomics
• Innovative Mass Spectrometry Techniques
• Cancer Epigenetics
• Metabolic Disorders & Metabolomics
• Stem Cell Proteomics
• Imaging & Single Cell Proteomics

About Meetings International:
Meetings International provides a Global Platform for Biochemistry Professionals, Biotech, Medical and Healthcare Professionals to Exchange Ideas, Knowledge and Networking at its 100+ International Conferences.

Market Analysis:
The global proteomics market is valued at USD 12.54 Billion in 2016. This market is expected to grow at a CAGR of 11.7% during the forecast period to reach USD 21.87 Billion by 2021. The global market exhibits potential for significant growth and is propelled by the increasing need for personalized medicine, R&D expenditure, technological advancements, and increased funding for proteomics projects. In this report, the global proteomics market is segmented on the basis of instrumentation technology, application, reagent, services & software, and region. On the basis of application, the market is segmented into drug discovery, clinical diagnostics, and other applications. The clinical diagnostics segment accounted for the largest share of the market in 2015. This is attributed to the increased understanding of the relevance of investigating and understanding patterns of protein expression for diseases and drug development.

Conference Sessions:
Track 1: Proteomics & System Biology
Proteomics is an emerging field that has been highly enabled by the human genome project. Proteins are the products of genes, the machinery of the cells in our bodies. When genes are disrupted, the proteins are also affected. When pathogens infect us, causing disease, proteins play a key role in signaling the presence and ridding us of these invaders. Almost every process that occurs in our cells – from the metabolization of simple sugar to the division of cells – is dependent on proteins for smooth operation. In general, proteomics seeks to detect and quantify as many proteins as possible.
Track 2: Chemical Proteomics & Profiling Drug Targets
Chemical proteomics is a branch and improving area of chemical biology that finds to design small molecule probes to understand protein function. In the context of natural products, chemical proteomics can be used to identify the protein binding partners or targets of small molecules in live cells. The direct detection of drug-protein interactions in living cells is a major challenge in drug discovery research. Recently, we introduced an approach termed thermal proteome profiling (TPP), which enables the monitoring of changes in protein thermal stability across the proteome using quantitative mass spectrometry.
Track 3: Multiomics for Precision Medicine
Systematical studies of clinical and pathological mechanisms and identification of optimal therapeutic targets through integrative analysis of multi-omics data from different levels and resources have become an important research direction of precision medicine, which would provide innovative perspectives on disease study and new theoretical basis for early diagnosis, personalized treatment and medicine guide.
Track 4: Analytical Proteomics & Genomics
Proteomics are applied to identify protein modification to determine the difference between a wild type and a genetically modified organism. It is also used to study protein-protein interactions involved in plant defence reactions. Genomics is the new science that deals with the identification of all the sequences in the entire genome and involves in the genetic make-up of organisms.The genome is a complete set of genes inside a cell. Genomics is the study of Genomic sequence is used to study the functions of the numerous genes such as functional genomics and to compare the genes in one organism with the another one i.e, comparative genomics, or to generate the 3-D structure of one or more proteins from each protein family, through this we can identify structural genomics. Analytical methods such as protein identification, analysis of protein primary structure and post-translational modifications by means of the most comprehensive technologies for proteomics, mass spectrometry and bioinformatics.
Track 5: Bioinformatics and Computational Proteomics
Bioinformatics is a combination of molecular biology and computer sciences. Bioinformatics is very important for the use of genomic information to understand human diseases and to identify new ways for gene-based drug discovery and development. Computational Proteomics is about the computational methods, algorithms, databases and methodologies used to process, manage, analyze and interpret the data produced in proteomics experiments. As in many scientific disciplines, the final goal of Computational Proteomics is to infer knowledge models (e.g. verify a hypothesis or identify proteins involved in a disease) from the inspection of biological samples.
Track 6: Clinical & Translational Proteomics
Clinical Proteomics includes all aspects of translational proteomics. As the research in molecular medicine field has moved beyond genomics to proteomics. Clinical proteomics studies can help researcher understand the characterization of cellular network, impact of the disease and its therapy. Over the years the field of proteomics has expanded with the development of mass-spectrometry to a broad and varied research areas of science. Incredible progress in instrumentation of mass-spectrometry has led to the sensitivity, accuracy and quick analysis and identification of proteins. With the advancement in science qualitative and quantitative differences in protein profiles of particular diseased vs. normal can be analyzed. Translational Proteomics involves areas of human proteomics using multi-disciplinary approaches to untangle complex disease processes.
Track 7: Innovative Fractionation & Enrichment Techniques
Phosphoproteins are often present in quite low abundance and tend to co-exist with their unphosphorylated isoform within the cell. To make their identification more practicable, the use of enrichment protocols is often required. The enrichment strategies can be performed either at the level of phosphoproteins or at the level of phospho-peptides. Both approaches have their advantages and disadvantages. Most enriching strategies are based on chemical modifications, affinity chromatography to capture peptides and proteins containing negatively charged phosphate groups onto a positively charged matrix, or immunoprecipitation by phospho-specific antibodies.
Track 8: Proteomics Technologies
The origin of proteomics technologies for global detection and quantitation of proteins creates new opportunities and challenges for those seeking to gain greater understanding of diseases. The high passing proteomics technologies are combining with the advanced bioinformatics and are extensively used to identify the molecular signatures of diseases based on protein pathways and signaling cascades. The mass spectrometry plays a vital role in the proteomics and has to become an indispensable tool for the molecular and cellular biology. While the potential is high, many challenges and issues remain to be unsolved, such as mining low abundant proteins and integration of proteomics with genomics and metabolomics data. Even so, proteomics is the base for constructing and extracting useful knowledge to biomedical research
Track 9: Biomedical Sciences In Proteomics
Biomedical research is generally known as medical research. And it is the basic research, applied research, or translational research conducted to aid and supports the development of knowledge in the field of medicine.Proteomics is used in many areas of research such as discovery of markers for diagnosis and vaccine candidates, understanding pathogenic mechanisms, and also in the study of expression patterns at different time points and also in response to different stimuli, and in elucidating the functional protein networks. Proteomics analysis involves in the sample preparation, protein separation, and protein identification.
Track 10: Innovative Mass Spectrometry Techniques
Mass spectrometers can acquire qualitative and quantitative information on a large scale to study protein expression, protein interactions and modifications, in complexes, organelles, cells and tissues. The currently available technological platforms and approaches offer a wide selection for proteomics experiments from low to high throughput, from shotgun discovery to targeted validation.
Track 11: Cancer Epigenetics
Epigenetics, the study of potentially heritable changes in the gene expression (active versus inactive genes) and that does not involve the changes to the underlying DNA sequence – a change in phenotype without a change in genotype and which in turn affects how cells read the genes. And also epigenetic change can have more damaging effects that can results in diseases like cancer. At least three systems including DNA methylation, histone modification and non-coding RNA (ncRNA) and associated gene silencing are currently considered to initiate and sustain epigenetic change. Cancer epigenetics is the study of somatically heritable changes to molecular processes that influence the flow of information between the DNA of cancer cells and their gene expression patterns. the technology most frequently used for the analysis of clinical tissue samples is the two-dimensional gel electrophoresis (2DE) are combined with the matrix assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS).
Track 12: Metabolic Disorders & Metabolomics
When abnormal chemical reactions occurs in your body and disrupt the process it is known as metabolic disorder. There are different groups of disorders. Some affect the breakdown of amino acids, carbohydrates, or lipids. Another group, mitochondrial diseases, affects the parts of the cells that produce the energy. Metabolomics ,it is the study of low molecular weight molecules or metabolites are found within cells and biological systems. The metabolome is a measure of the inputs and outputs of biological pathways and it is often considered to more representative of the functional state of a cell than other ‘omics measures such as genomics or proteomics. In addition, many metabolites are conserved across the various animal species, facilitating the extrapolation of research findings in the laboratory animals to humans. Common technologies are used for measuring the metabolome include the mass spectrometry (MS) and also nuclear magnetic resonance spectroscopy (NMR), which can detect the hundreds to thousands of unique chemical entities (UCE).
Track 12: Stem Cell Proteomics
Proteomics it is a series of technology and platforms driven by advancements in mass spectrometry and bioinformatics that encompass protein identification, the relative quantitation of proteins and peptides, their subcellular localization, and studies of post-translational modifications and protein-protein interactions. Stem cell biology has been influenced by these approaches and has evolved in the post-genomics era. Implementation of proteomic applications brought many changes in stem cell biology.
Track 14: Imaging & Single Cell Proteomics
Single-cell genomics is advancing rapidly and it is generating many new insights into complex biological systems, ranging from the diversity of microbial ecosystems to the genomics of human cancer. It focus on the technical challenges of making measurements that start from a single molecule of DNA, and then explore how some of these recent methodological advancements have enabled the discovery of unexpected new biology. Methods for the genomic analysis at the single-cell resolution enable the new understanding of the complex biological phenomena. Single-cell techniques are ranging from flow cytometry and microfluidics to PCR and sequencing these are used to understand the cellular composition of complex tissues, it helps to find new microbial species and perform genome-wide haplotyping.